Galectin Therapeutics Stock Analysis
| GALT Stock | USD 1.25 0.02 1.63% |
Galectin Therapeutics is undervalued with Real Value of 3.68 and Target Price of 11.0. The main objective of Galectin Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Galectin Therapeutics is worth, separate from its market price. There are two main types of Galectin Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Galectin Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Galectin Therapeutics is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day. Galectin Stock trading window is adjusted to America/New York timezone.
Galectin |
Galectin Stock Analysis Notes
About 31.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.73. Galectin Therapeutics had not issued any dividends in recent years. The entity had 1:6 split on the 23rd of March 2012. Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia. Galectin Therapeutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people. To learn more about Galectin Therapeutics call the company at (678) 620-3186 or check out https://galectintherapeutics.com.Galectin Therapeutics Investment Alerts
| Galectin Therapeutics generated a negative expected return over the last 90 days | |
| Galectin Therapeutics has high historical volatility and very poor performance | |
| Galectin Therapeutics may become a speculative penny stock | |
| Galectin Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (41.07 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Galectin Therapeutics currently holds about 15.83 M in cash with (32.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.27. | |
| Galectin Therapeutics has a very weak financial position based on the latest SEC disclosures | |
| Roughly 31.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Callicutt Jack W of 60000 shares of Galectin Therapeutics subject to Rule 16b-3 |
Galectin Therapeutics Upcoming and Recent Events
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Galectin Largest EPS Surprises
Earnings surprises can significantly impact Galectin Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-11 | 2024-09-30 | -0.2 | -0.18 | 0.02 | 10 | ||
2020-08-10 | 2020-06-30 | -0.09 | -0.11 | -0.02 | 22 | ||
2018-11-13 | 2018-09-30 | -0.09 | -0.07 | 0.02 | 22 |
Galectin Therapeutics Thematic Classifications
In addition to having Galectin Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
 | Israel Wall StreetLarge Israel companies traded on major USA exchanges |
Galectin Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Soltis Investment Advisors, Llc | 2024-09-30 | 140.8 K | Cutter & Co Brokerage, Inc. | 2024-09-30 | 115.5 K | Cambridge Invest Research Advisors, Inc. | 2024-09-30 | 114.7 K | Lpl Financial Corp | 2024-09-30 | 81.9 K | Susquehanna International Group, Llp | 2024-09-30 | 81.5 K | Sanctuary Advisors, Llc | 2024-09-30 | 79.1 K | Charles Schwab Investment Management Inc | 2024-09-30 | 65.1 K | Retirement Guys Formula Llc | 2024-09-30 | 63.8 K | Traynor Capital Management, Inc | 2024-12-31 | 55.7 K | Vanguard Group Inc | 2024-09-30 | 2.1 M | Blackrock Inc | 2024-09-30 | 1.6 M |
Galectin Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 78.45 M.Galectin Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.31) | (1.38) | |
| Return On Capital Employed | (3.50) | (3.32) | |
| Return On Assets | (1.31) | (1.38) | |
| Return On Equity | 0.78 | 0.74 |
Management Efficiency
Galectin Therapeutics has return on total asset (ROA) of (1.0387) % which means that it has lost $1.0387 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (37.2795) %, meaning that it created substantial loss on money invested by shareholders. Galectin Therapeutics' management efficiency ratios could be used to measure how well Galectin Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.38 in 2025. Return On Capital Employed is likely to gain to -3.32 in 2025. Total Current Liabilities is likely to gain to about 18.9 M in 2025. Liabilities And Stockholders Equity is likely to gain to about 34.1 M in 2025| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (1.15) | (1.09) | |
| Tangible Book Value Per Share | (1.15) | (1.09) | |
| Enterprise Value Over EBITDA | (831.25) | (789.69) | |
| Price Book Value Ratio | (1.91) | (1.81) | |
| Enterprise Value Multiple | (831.25) | (789.69) | |
| Price Fair Value | (1.91) | (1.81) | |
| Enterprise Value | 99.5 M | 104.5 M |
The decision-making processes within Galectin Therapeutics are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Technical Drivers
As of the 1st of February, Galectin Therapeutics retains the Standard Deviation of 8.72, market risk adjusted performance of (0.87), and Risk Adjusted Performance of (0.05). Galectin Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Galectin Therapeutics Price Movement Analysis
The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Galectin Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Galectin Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Galectin Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Galectin Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Galectin Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Galectin Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Galectin Therapeutics Outstanding Bonds
Galectin Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Galectin Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Galectin bonds can be classified according to their maturity, which is the date when Galectin Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| ADGLXY 2625 31 MAR 36 Corp BondUS36321PAB67 | View | |
| ADGLXY 175 30 SEP 27 Corp BondUS36321PAA84 | View | |
| ADGLXY 216 31 MAR 34 Corp BondUS36321PAD24 | View | |
| ADGLXY 294 30 SEP 40 Corp BondUS36321PAE07 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View |
Galectin Therapeutics Predictive Daily Indicators
Galectin Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Galectin Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Galectin Therapeutics Forecast Models
Galectin Therapeutics' time-series forecasting models are one of many Galectin Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Galectin Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Galectin Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Galectin Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Galectin shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Galectin Therapeutics. By using and applying Galectin Stock analysis, traders can create a robust methodology for identifying Galectin entry and exit points for their positions.
| Last Reported | Projected for Next Year |
Current Galectin Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Galectin analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Galectin analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 11.0 | Hold | 1 | Odds |
Most Galectin analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Galectin stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Galectin Therapeutics, talking to its executives and customers, or listening to Galectin conference calls.
Galectin Stock Analysis Indicators
Galectin Therapeutics stock analysis indicators help investors evaluate how Galectin Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Galectin Therapeutics shares will generate the highest return on investment. By understating and applying Galectin Therapeutics stock analysis, traders can identify Galectin Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 18.6 M | |
| Long Term Debt | 71.7 M | |
| Common Stock Shares Outstanding | 60.2 M | |
| Total Stockholder Equity | -60.2 M | |
| Property Plant And Equipment Net | 53 K | |
| Cash And Short Term Investments | 25.7 M | |
| Cash | 25.7 M | |
| Accounts Payable | 6.4 M | |
| Net Debt | 46.1 M | |
| 50 Day M A | 1.7898 | |
| Total Current Liabilities | 15.7 M | |
| Other Operating Expenses | 38.1 M | |
| Non Current Assets Total | 490 K | |
| Non Currrent Assets Other | 437 K | |
| Stock Based Compensation | 2.3 M |
Additional Tools for Galectin Stock Analysis
When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.